Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data.

Poynard T, Lassailly G, Diaz E, Clement K, Caïazzo R, Tordjman J, Munteanu M, Perazzo H, Demol B, Callafe R, Pattou F, Charlotte F, Bedossa P, Mathurin P, Ratziu V; FLIP consortium..

PLoS One. 2012;7(3):e30325. doi: 10.1371/journal.pone.0030325.

2.

Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity.

Lassailly G, Caiazzo R, Hollebecque A, Buob D, Leteurtre E, Arnalsteen L, Louvet A, Pigeyre M, Raverdy V, Verkindt H, Six MF, Eberle C, Patrice A, Dharancy S, Romon M, Pattou F, Mathurin P.

Eur J Gastroenterol Hepatol. 2011 Jun;23(6):499-506. doi: 10.1097/MEG.0b013e3283464111.

PMID:
21499110
3.

Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease.

Ratziu V, Massard J, Charlotte F, Messous D, Imbert-Bismut F, Bonyhay L, Tahiri M, Munteanu M, Thabut D, Cadranel JF, Le Bail B, de Ledinghen V, Poynard T; LIDO Study Group.; CYTOL study group..

BMC Gastroenterol. 2006 Feb 14;6:6.

4.

Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease.

Poynard T, Ratziu V, Charlotte F, Messous D, Munteanu M, Imbert-Bismut F, Massard J, Bonyhay L, Tahiri M, Thabut D, Cadranel JF, Le Bail B, de Ledinghen V; LIDO Study Group.; CYTOL study group..

BMC Gastroenterol. 2006 Nov 10;6:34.

5.

FibroTest-ActiTest as a non-invasive marker of liver fibrosis.

Halfon P, Munteanu M, Poynard T.

Gastroenterol Clin Biol. 2008 Sep;32(6 Suppl 1):22-39. doi: 10.1016/S0399-8320(08)73991-5.

6.

The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis.

Poynard T, Ratziu V, Naveau S, Thabut D, Charlotte F, Messous D, Capron D, Abella A, Massard J, Ngo Y, Munteanu M, Mercadier A, Manns M, Albrecht J.

Comp Hepatol. 2005 Dec 23;4:10.

7.

Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference.

Munteanu M, Tiniakos D, Anstee Q, Charlotte F, Marchesini G, Bugianesi E, Trauner M, Romero Gomez M, Oliveira C, Day C, Dufour JF, Bellentani S, Ngo Y, Traussnig S, Perazzo H, Deckmyn O, Bedossa P, Ratziu V, Poynard T; FLIP Consortium and the FibroFrance Group..

Aliment Pharmacol Ther. 2016 Oct;44(8):877-89. doi: 10.1111/apt.13770.

8.

Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus.

Poynard T, Ngo Y, Marcellin P, Hadziyannis S, Ratziu V, Benhamou Y; Adefovir Dipivoxil 437 and 438 Study Groups..

J Viral Hepat. 2009 Mar;16(3):203-13. doi: 10.1111/j.1365-2893.2008.01065.x.

PMID:
19175871
9.

The Distribution of Liver Steatosis, Fibrosis, Steatohepatitis and Inflammation Activity in Alcoholics According to FibroMax Test.

Gudowska M, Wojtowicz E, Cylwik B, Gruszewska E, Chrostek L.

Adv Clin Exp Med. 2015 Sep-Oct;24(5):823-7. doi: 10.17219/acem/28485.

10.

Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease.

Naveau S, Gaudé G, Asnacios A, Agostini H, Abella A, Barri-Ova N, Dauvois B, Prévot S, Ngo Y, Munteanu M, Balian A, Njiké-Nakseu M, Perlemuter G, Poynard T.

Hepatology. 2009 Jan;49(1):97-105. doi: 10.1002/hep.22576.

PMID:
19053048
11.

Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia.

Perazzo H, Munteanu M, Ngo Y, Lebray P, Seurat N, Rutka F, Couteau M, Jacqueminet S, Giral P, Monneret D, Imbert-Bismut F, Ratziu V, Hartemann-Huertier A, Housset C, Poynard T; FLIP Consortium..

Aliment Pharmacol Ther. 2014 Nov;40(9):1081-93. doi: 10.1111/apt.12946.

12.

Noninvasive biomarkers FibroTest and ActiTest versus liver biopsy in chronic hepatitis C patients: the Middle East experience.

Yakoob R, Bozom IA, Thandassery RB, Rahman MO, Derbala MF, Mohannadi MJ, John AK, Sharma M, Wani H, Kaabi SA.

Ann Gastroenterol. 2015 Apr-Jun;28(2):265-270.

13.

The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases.

Sebastiani G, Castera L, Halfon P, Pol S, Mangia A, Di Marco V, Pirisi M, Voiculescu M, Bourliere M, Alberti A.

Aliment Pharmacol Ther. 2011 Nov;34(10):1202-16. doi: 10.1111/j.1365-2036.2011.04861.x.

14.

A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C.

Ngo Y, Munteanu M, Messous D, Charlotte F, Imbert-Bismut F, Thabut D, Lebray P, Thibault V, Benhamou Y, Moussalli J, Ratziu V, Poynard T.

Clin Chem. 2006 Oct;52(10):1887-96.

15.

FibroTest and Fibroscan performances revisited in patients with chronic hepatitis C. Impact of the spectrum effect and the applicability rate.

Poynard T, de Ledinghen V, Zarski JP, Stanciu C, Munteanu M, Vergniol J, France J, Trifan A, Moussalli J, Lebray P, Thabut D, Ratziu V.

Clin Res Hepatol Gastroenterol. 2011 Nov;35(11):720-30. doi: 10.1016/j.clinre.2011.07.003.

PMID:
21852224
16.

Meta-analyses of FibroTest diagnostic value in chronic liver disease.

Poynard T, Morra R, Halfon P, Castera L, Ratziu V, Imbert-Bismut F, Naveau S, Thabut D, Lebrec D, Zoulim F, Bourliere M, Cacoub P, Messous D, Munteanu M, de Ledinghen V.

BMC Gastroenterol. 2007 Oct 15;7:40.

17.

Correlation between liver biopsy and fibrotest in the evaluation of hepatic fibrosis in patients with chronic hepatitis C.

Said Y, Salem M, Mouelhi L, Mekki H, Houissa F, Ben Rejeb M, Moussa A, Trabelsi S, Debbeche R, Bouzaidi S, Najjar T.

Tunis Med. 2010 Aug;88(8):573-8.

18.

Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease.

McPherson S, Stewart SF, Henderson E, Burt AD, Day CP.

Gut. 2010 Sep;59(9):1265-9. doi: 10.1136/gut.2010.216077.

PMID:
20801772
19.

Comparison of FibroTest-ActiTest with histopathology in demonstrating fibrosis and necroinflammatory activity in chronic hepatitis B and C.

Uyar C, Akcam FZ, Ciris M, Kaya O, Kockar C, Isler M.

Indian J Pathol Microbiol. 2010 Jul-Sep;53(3):470-5. doi: 10.4103/0377-4929.68281.

20.

Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C.

Poynard T, Imbert-Bismut F, Munteanu M, Messous D, Myers RP, Thabut D, Ratziu V, Mercadier A, Benhamou Y, Hainque B.

Comp Hepatol. 2004 Sep 23;3(1):8.

Items per page

Supplemental Content

Support Center